Soligenix announces successful protection using a bivalent thermostabilized filovirus vaccine

Bivalent vaccine provides 100% protection in non-human primates against both sudan ebolavirus and marburg marburgvirus only subunit (protein) vaccine platform shown to protect against potentially lethal ebola and marburg viruses princeton, n.j. , june 23, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (nhps) against lethal marburg marburgvirus (marv) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with sterile water immediately prior to use.
SNGX Ratings Summary
SNGX Quant Ranking